Towards optimizing infliximab therapy in severe sarcoidosis patients: personalized medicine
Completed
- Conditions
- Besnier Boeck DiseaseInterstitiel LungdiseaseSarcoidosis100218771002497010040792
- Registration Number
- NL-OMON39486
- Lead Sponsor
- Sint Antonius Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 52
Inclusion Criteria
- patients diagnosed with sarcoidosis.
- patients treated with infliximab
- capability of giving informed consent
Exclusion Criteria
· vaccination with live viral or bacterial vaccines within the previous 3 months, or within the next 3 months of the last doses.
· cases of active or untreated latent tuberculosis (by mantoux-Elispot/TBC-IGRA)
· serious infections within the past 2 months
· serious right-sided heart failure or cor polmunale
· known malignancy
· Hepatitis B
· paitients with allergic reactions to the monocolonal antibodies or their fragments
· oppotunistic infections last 6 months
· HIV
· transplantation
· pregnancy or bearstfeeding
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method